Form 4 for PFE Pfizer
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001225208-23-002818 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-24 | 2023-02-22 | PFE | SAHNI PAYAL | EVP | M - OptEx | $30.17 | +15.2K | 32.7K | +87% | +$458.9K |
| DM | 2023-02-24 | 2023-02-22 | PFE | SAHNI PAYAL | EVP | F - Tax | $43.45 | -11.5K | 30.5K | -27% | -$498.1K |
| DM | 2023-02-24 | 2023-02-23 | PFE | SAHNI PAYAL | EVP | A - Grant | $0.00 | +85.9K | 45.9K | New | $0 |
| D | 2023-02-24 | 2023-02-22 | PFE | SAHNI PAYAL | EVP | M - OptEx | $0.00 | -15.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-22 | M | A | 15,209 | $30.17 | 32,671 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 2 | Common | Common Stock | 2023-02-22 | F | D | 9,259 | $43.70 | 21,206 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 3 | Common | Common Stock | 2023-02-22 | F | D | 2,206 | $42.38 | 30,465 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 4 | Derivative | Stock Appreciation Rights | 2023-02-23 | A | A | 39,965 | $0.00 | 39,965 | D | $42.30 · 2030-02-23 to 2030-02-23 | 39,965 Common Stock | (F6) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |
| 5 | Derivative | Stock Appreciation Rights | 2023-02-22 | M | D | 15,209 | $0.00 | 0 | D | $30.17 · 2023-02-22 to 2023-02-22 | 15,209 Common Stock | |
| 6 | Derivative | Stock Appreciation Rights | 2023-02-23 | A | A | 45,920 | $0.00 | 45,920 | D | $42.30 · 2028-02-23 to 2028-02-23 | 45,920 Common Stock | (F5) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |